Argent BioPharma Limited (ASX:RGT)

Market Cap	6.00M -2.2%
Revenue (ttm)	347.78K +17.6%
Net Income	-8.62M
EPS	-0.12
Shares Out	111.11M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	193,390
Open	0.0480
Previous Close	0.0500
Day's Range	0.0460 - 0.0540
52-Week Range	0.0330 - 0.3200
Beta	0.41
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Argent BioPharma

Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally. The company’s principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer’s. It i...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2014
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: RGT

Financial Performance

In fiscal year 2025, Argent BioPharma's revenue was 180,565, a decrease of -79.74% compared to the previous year's 891,083. Losses were -17.84 million, 1.79% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 21, 2026

Data Sources Report a data error